Drugs / L-Nitro-Monomethyl-Arginine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02245165 | Jun 2013 → May 2014 | intestinal motility disease, salivary gland disorder | Uppsala University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Nitro-Monomethyl-Arginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02245165 ↗ |
| Known as | LNMMA | “L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV” NCT02245165 ↗ |
| Action | Inhibit | “NO synthase inhibitor” NCT02245165 ↗ |
| Route | Intravenous | “10 mg/kg intravenously” NCT02245165 ↗ |